Advertisement

Further Assessment of the Relay Hepatocyte Assay for Determination of Intrinsic Clearance of Slowly Metabolised Compounds Using Radioactivity Monitoring and LC–MS Methods

  • Renata MurgasovaEmail author
Original Research Article

Abstract

Background and Objectives

Low-clearance drugs are widely used by industry mostly because of their often longer half-life, allowing for lower or less frequent dosing. Nevertheless, prediction of human clearance for these molecules from in vitro models presents a great challenge for pharmaceutical scientists. The objective of this study was to further characterise the predictive accuracy of the relay hepatocyte assay using 14C and 3H labelled proprietary compounds with a low extraction ratio and the known clearance mechanism in rats. Highly permeable compounds cleared by metabolism as well as rate limitation by transport were included in this study.

Methods

Blood clearance was determined from concentration–time profiles following intravenous dosing to rats. In vitro clearance was determined from the single concentration parent depletion-time profiles throughout the incubation period of up to 20 h (five relays) using radioactivity monitoring in tandem with mass spectrometry. A new approach was proposed to correct concentrations for loss and dilution during the relay steps. Clearance was predicted with a standard well-stirred model for the liver and predicted values were then compared with observed data to evaluate method accuracy.

Results

The results showed that intrinsic clearance values predicted using the relay hepatocyte assay from either radioactivity or mass spectrometry concentration data were comparable. A significant difference in prediction accuracy between the permeable compounds cleared by hepatic metabolism (about 2-fold) and the compound that was the hepatic uptake substrate (5- to 6-fold of actual) was demonstrated.

Conclusions

The relay method is effective in predicting in vivo clearance for the compounds that are cleared via hepatic metabolism but tends to be notably underpredictive for drugs that rely on uptake transport. Consistent with the overall trend toward underprediction of hepatic clearance from the in vitro models prevalently used in the pharmaceutical industry, all values predicted from the hepatocyte relay method were lower than observed.

Notes

Acknowledgements

The author would like to thank Ester Tor Carreras for her specific contribution to the laboratory analysis of this study.

Compliance with Ethical Standards

Funding

No source of funding.

Conflict of Interest

The author declares no conflict of interest.

Ethics Approval

Animal experiments were approved by the local Animal Welfare Committee. All applicable international, national, and/or institutional guidelines for care and use of animals were followed.

References

  1. 1.
    McGinnity DF, Soars MG, Urbanowicz RA, Riley RJ. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab Disp. 2004;32:1247–53.  https://doi.org/10.1124/dmd.104.000026.CrossRefGoogle Scholar
  2. 2.
    Hutzler MJ, Ring BJ, Anderson SR. Low-turnover drug molecules: a current challenge for drug metabolism scientist. Drug Metab Disp. 2015;43:1917–28.  https://doi.org/10.1124/dmd.115.066431.CrossRefGoogle Scholar
  3. 3.
    Bonn B, Svanberg P, Janefeldt A, Hultman LA, Grime K. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell-co-culture with plated primary hepatocytes and HepaRG. Drug Metab Disp. 2016;44:527–33.  https://doi.org/10.1124/dmd.115.067769.CrossRefGoogle Scholar
  4. 4.
    Di L, Obach S. Addressing challenges of low clearance in drug research. AAPS J. 2015;17(2):352–7.  https://doi.org/10.1208/s12248-014-9691-7.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Zanelli U, Michna T, Petersson C. Determination of low intrinsic clearance in vitro: the benefit of a novel internal standard in human hepatocyte incubations. Xenobiotica. 2018;49(4):381–7.  https://doi.org/10.1080/00498254.2018.1451010.CrossRefPubMedGoogle Scholar
  6. 6.
    Peng CC, Doshi U, Prakash Ch, Li AP. A novel plated hepatocyte relay assay (PHRA) for in vitro evaluation of hepatic metabolic clearance of slowly metabolized compounds. Drug Metab Lett. 2016;10:3–15.  https://doi.org/10.2174/1872312809666150818111500.CrossRefPubMedGoogle Scholar
  7. 7.
    Di L, Trapa P, Obach SR, Atkinson K, Yi-An B, Wolford AC, Tan B, McDonald TS, Lai Y, Tremaine LM. A novel relay method for determining low-clearance values. Drug Metab Disp. 2012;40(9):1860–5.  https://doi.org/10.1124/dmd.112.046425.CrossRefGoogle Scholar
  8. 8.
    Di L, Atkinson CC, Orozco C, Funk C, Zhang H, McDonald TS, Tan B, Lin J, Chang C, Obach SR. In vitro–in vivo correlation for low clearance compounds using hepatocyte relay method. Drug Metab Disp. 2013;41(12):2018–23.  https://doi.org/10.1124/dmd.115.067769.CrossRefGoogle Scholar
  9. 9.
    Bonn B, Svanberg P, Janefeldt A, Hultman I, Grime K. Determination of human hepatocyte intrinsic clearance for slowly metabolized compounds: comparison of a primary hepatocyte/stromal cell co-culture with plated primary hepatocytes and HepaRH. Drug Metab Disp. 2016;44(4):527–33.  https://doi.org/10.1124/dmd.115.067769.CrossRefGoogle Scholar
  10. 10.
    Carlile DJ, Zomorodi K, Houston JB. Scaling factors to relate drug metabolic clearance in hepatic microsomes, isolated hepatocytes, and the intact liver: studies with induced livers involving diazepam. Drug Metab Dispos. 1997;25(8):903–11.PubMedGoogle Scholar
  11. 11.
    Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–5.CrossRefGoogle Scholar
  12. 12.
    Barter Z, Bayliss M, Beaune P, Boobis AR, Carlile DJ, Edwards RJ, Houston JB, Lake BG, Lipscomb JC, Pelkonen OR, Tucker GT, Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr Drug Metab. 2007;8(1):33–45.CrossRefGoogle Scholar
  13. 13.
    Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab Disp. 1999;27(11):1350–9.Google Scholar
  14. 14.
    Hayes KA, Brennan B, Chenery R, Houston JB. In vivo disposition of caffeine predicted from hepatic microsomal and hepatocyte data. Drug Metab Disp. 1994;23(3):349–53.Google Scholar
  15. 15.
    Nakazawa K, Tanaka H, Arima M. The effect of caffeine ingestion on pharmacokinetics of caffeine and its metabolites after a single administration in pregnant rats. J Pharmacobiodyn. 1985;8:151–60.CrossRefGoogle Scholar
  16. 16.
    Khanna KL, Rao GS, Cornish HH. Metabolism of caffeine - 3H in the rat. Toxicol Appl Pharmacol. 1972;23:720–30.CrossRefGoogle Scholar
  17. 17.
    Rowland M, Pang KS. Commentary on “The universally unrecognized assumption in predicting drug clearance and organ extraction ratio”. Clin Pharmacol Ther. 2018;103(3):386–8.  https://doi.org/10.1002/cpt.921.CrossRefPubMedGoogle Scholar
  18. 18.
    Wood FL, Houston JB, Hallifax D. Clearance prediction methodology needs fundamental improvement: trends common to rat and human hepatocyte/microsomes and implication for experimental methodology. Drug Metab Disp. 2017;45:1178–88.  https://doi.org/10.1124/dmd.117.077040.CrossRefGoogle Scholar
  19. 19.
    Pang SK, Rowland M. Hepatic clearance of drugs. Theoretical considerations of a “Well-Stirred” Model and a “Parallel Tube” Model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharm Biopharm. 1977;5(6):625–53.CrossRefGoogle Scholar
  20. 20.
    Varma MV, Steyn SJ, Allerton C, El-Kattan AF. Predicting clearance mechanism in drug discovery: extended clearance classification system (ECCS). Pharm Res. 2015;32:3785–802.  https://doi.org/10.1007/s11095-015-1749-4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.PKS, Novartis Institute for Biomedical Research, Novartis Pharma AGBaselSwitzerland

Personalised recommendations